Clinical trial
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer…
NCT00128310 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00128310 |
|---|---|
| Title | Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients |
| Official title | Randomized Phase III Trial Comparing Vinorelbine vs. Gemcitabine Plus Vinorelbine in Patients With Advanced Breast Cancer, Previously Treated With Anthracyclines and Taxanes |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Vinorelbine, Gemcitabine |
| Enrollment | 252 |
| Start date | Jan 18, 2001 |
| Primary completion | Aug 15, 2006 |
| Completion | Jan 24, 2008 |
| First posted | Aug 9, 2005 |
| Last update posted | May 31, 2023 |
| Countries | Spain, Venezuela |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: